| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 4 | 2019 | 425 | 1.740 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2020 | 121 | 1.420 |
Why?
|
| Heart Defects, Congenital | 15 | 2024 | 1802 | 1.270 |
Why?
|
| Heart Valve Prosthesis | 3 | 2023 | 292 | 1.120 |
Why?
|
| Pulmonary Valve | 2 | 2019 | 96 | 1.100 |
Why?
|
| Angioplasty, Balloon | 3 | 2017 | 161 | 1.090 |
Why?
|
| Cardiac Catheterization | 8 | 2023 | 634 | 0.980 |
Why?
|
| Treatment Outcome | 22 | 2024 | 12103 | 0.860 |
Why?
|
| Mustard Plant | 1 | 2022 | 4 | 0.840 |
Why?
|
| Vacuum Curettage | 1 | 2022 | 6 | 0.840 |
Why?
|
| Stents | 6 | 2020 | 866 | 0.790 |
Why?
|
| Pulmonary Artery | 4 | 2023 | 439 | 0.780 |
Why?
|
| Heart-Assist Devices | 4 | 2022 | 1023 | 0.730 |
Why?
|
| Septal Occluder Device | 2 | 2019 | 43 | 0.730 |
Why?
|
| Aortic Valve | 3 | 2019 | 428 | 0.700 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2019 | 192 | 0.660 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 50 | 0.650 |
Why?
|
| Stenosis, Pulmonary Artery | 1 | 2019 | 5 | 0.650 |
Why?
|
| Dyspnea | 1 | 2020 | 149 | 0.650 |
Why?
|
| Aortic Coarctation | 2 | 2017 | 105 | 0.650 |
Why?
|
| Foramen Ovale, Patent | 1 | 2019 | 15 | 0.640 |
Why?
|
| Prostheses and Implants | 1 | 2020 | 151 | 0.630 |
Why?
|
| Superior Vena Cava Syndrome | 2 | 2016 | 17 | 0.620 |
Why?
|
| Hypoxia | 1 | 2020 | 245 | 0.620 |
Why?
|
| Heart Diseases | 2 | 2013 | 483 | 0.590 |
Why?
|
| Aortic Diseases | 1 | 2020 | 197 | 0.580 |
Why?
|
| Transposition of Great Vessels | 2 | 2017 | 132 | 0.570 |
Why?
|
| Hypertension, Pulmonary | 4 | 2017 | 431 | 0.570 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2017 | 1102 | 0.570 |
Why?
|
| Norwood Procedures | 1 | 2017 | 100 | 0.530 |
Why?
|
| Bioprosthesis | 1 | 2017 | 111 | 0.530 |
Why?
|
| Heart Failure | 5 | 2022 | 2125 | 0.520 |
Why?
|
| Shock, Cardiogenic | 1 | 2018 | 189 | 0.520 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 325 | 0.510 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2014 | 58 | 0.500 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2017 | 141 | 0.490 |
Why?
|
| Arterial Switch Operation | 1 | 2015 | 22 | 0.480 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2015 | 28 | 0.480 |
Why?
|
| Cardiology Service, Hospital | 1 | 2014 | 15 | 0.460 |
Why?
|
| Behcet Syndrome | 1 | 2014 | 16 | 0.460 |
Why?
|
| Coronary Aneurysm | 1 | 2014 | 34 | 0.450 |
Why?
|
| Hospitals, Pediatric | 3 | 2018 | 780 | 0.450 |
Why?
|
| Hemodynamics | 4 | 2020 | 850 | 0.440 |
Why?
|
| Health Resources | 1 | 2014 | 116 | 0.420 |
Why?
|
| Aneurysm, False | 1 | 2014 | 101 | 0.410 |
Why?
|
| Adult | 22 | 2024 | 29039 | 0.380 |
Why?
|
| Humans | 40 | 2024 | 123180 | 0.380 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 103 | 0.340 |
Why?
|
| Women's Health | 1 | 2011 | 130 | 0.330 |
Why?
|
| Prosthesis Design | 4 | 2019 | 667 | 0.310 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2020 | 241 | 0.300 |
Why?
|
| Female | 24 | 2024 | 65428 | 0.270 |
Why?
|
| Fontan Procedure | 3 | 2019 | 182 | 0.240 |
Why?
|
| Retrospective Studies | 13 | 2024 | 15981 | 0.240 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2024 | 218 | 0.230 |
Why?
|
| Young Adult | 10 | 2018 | 8870 | 0.220 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 63 | 0.210 |
Why?
|
| Ventricular Function, Left | 2 | 2017 | 500 | 0.200 |
Why?
|
| Child | 8 | 2022 | 24208 | 0.190 |
Why?
|
| Adolescent | 12 | 2019 | 19087 | 0.190 |
Why?
|
| Hospital Mortality | 4 | 2017 | 1004 | 0.190 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2018 | 628 | 0.190 |
Why?
|
| Hope | 1 | 2020 | 13 | 0.170 |
Why?
|
| Familial Primary Pulmonary Hypertension | 2 | 2017 | 19 | 0.160 |
Why?
|
| Solutions | 1 | 2019 | 65 | 0.160 |
Why?
|
| Anticoagulants | 3 | 2022 | 585 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 25 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 175 | 0.160 |
Why?
|
| Male | 17 | 2024 | 60022 | 0.160 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2019 | 112 | 0.150 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 623 | 0.150 |
Why?
|
| Time Factors | 6 | 2024 | 6201 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 112 | 0.140 |
Why?
|
| Syndrome | 1 | 2020 | 1114 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2018 | 84 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 203 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 126 | 0.140 |
Why?
|
| Heterografts | 1 | 2017 | 179 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 197 | 0.140 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 35 | 0.140 |
Why?
|
| Vena Cava, Superior | 1 | 2016 | 55 | 0.130 |
Why?
|
| Ductus Arteriosus | 1 | 2017 | 64 | 0.130 |
Why?
|
| Middle Aged | 9 | 2023 | 25980 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2022 | 854 | 0.130 |
Why?
|
| Executive Function | 1 | 2016 | 104 | 0.130 |
Why?
|
| Femoral Artery | 1 | 2016 | 190 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 313 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 143 | 0.120 |
Why?
|
| Heart Arrest | 1 | 2019 | 341 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2017 | 3007 | 0.120 |
Why?
|
| Fluoroscopy | 1 | 2015 | 89 | 0.120 |
Why?
|
| Thoracotomy | 1 | 2015 | 108 | 0.120 |
Why?
|
| Pacemaker, Artificial | 1 | 2016 | 170 | 0.120 |
Why?
|
| Pulmonary Circulation | 1 | 2015 | 121 | 0.120 |
Why?
|
| Aorta | 1 | 2017 | 541 | 0.110 |
Why?
|
| Survivors | 1 | 2016 | 345 | 0.110 |
Why?
|
| Risk Factors | 6 | 2018 | 10000 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 958 | 0.110 |
Why?
|
| Swine | 1 | 2017 | 1155 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2015 | 3332 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 366 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2014 | 67 | 0.110 |
Why?
|
| Thrombosis | 1 | 2018 | 520 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 228 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2015 | 945 | 0.110 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 162 | 0.110 |
Why?
|
| Coronary Vessels | 1 | 2017 | 525 | 0.110 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 152 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 269 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 236 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2014 | 457 | 0.100 |
Why?
|
| Survival Rate | 2 | 2018 | 1995 | 0.100 |
Why?
|
| Echocardiography | 1 | 2018 | 1070 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 2108 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 264 | 0.100 |
Why?
|
| Cognition | 1 | 2016 | 735 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1240 | 0.090 |
Why?
|
| Infant | 4 | 2019 | 12323 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2014 | 376 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2014 | 527 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2011 | 133 | 0.090 |
Why?
|
| Age Factors | 2 | 2014 | 2801 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2838 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 184 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 507 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5048 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 516 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 481 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1650 | 0.080 |
Why?
|
| Incidence | 2 | 2018 | 3050 | 0.080 |
Why?
|
| Texas | 2 | 2014 | 3548 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2022 | 671 | 0.070 |
Why?
|
| United States | 5 | 2018 | 10618 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 619 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1069 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3098 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 2024 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1225 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 1733 | 0.060 |
Why?
|
| Amiodarone | 1 | 2024 | 45 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1259 | 0.060 |
Why?
|
| Infant, Newborn | 4 | 2019 | 8089 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 60 | 0.050 |
Why?
|
| Pregnancy | 2 | 2014 | 7124 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2019 | 13862 | 0.050 |
Why?
|
| Aged | 3 | 2014 | 19072 | 0.050 |
Why?
|
| Prognosis | 1 | 2011 | 4508 | 0.050 |
Why?
|
| Heart Rate | 1 | 2024 | 585 | 0.050 |
Why?
|
| Prevalence | 3 | 2012 | 2405 | 0.050 |
Why?
|
| Warfarin | 1 | 2022 | 119 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 459 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 1418 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 125 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 123 | 0.040 |
Why?
|
| Comorbidity | 2 | 2012 | 1498 | 0.030 |
Why?
|
| Phlebography | 1 | 2016 | 51 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 199 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2017 | 113 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 87 | 0.030 |
Why?
|
| Length of Stay | 2 | 2012 | 1284 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 33728 | 0.030 |
Why?
|
| Reaction Time | 1 | 2016 | 169 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 376 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 1090 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 188 | 0.030 |
Why?
|
| Attention | 1 | 2016 | 194 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 437 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1083 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1390 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 921 | 0.030 |
Why?
|
| Phenylpropionates | 1 | 2011 | 3 | 0.020 |
Why?
|
| Reoperation | 1 | 2015 | 819 | 0.020 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2011 | 14 | 0.020 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2011 | 20 | 0.020 |
Why?
|
| Heart Atria | 1 | 2014 | 310 | 0.020 |
Why?
|
| Pyridazines | 1 | 2011 | 49 | 0.020 |
Why?
|
| Epoprostenol | 1 | 2011 | 67 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 767 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 671 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 565 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2548 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 259 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3260 | 0.020 |
Why?
|
| Transition to Adult Care | 1 | 2011 | 119 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1245 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 397 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2011 | 195 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 961 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 3377 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2599 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 4709 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1597 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 6028 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 850 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3518 | 0.010 |
Why?
|